Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Biostatistics and Clinical Epidemiology Service, National Institutes of Health Clinical Center, Bethesda, Maryland.
Kidney360. 2023 Mar 1;4(3):349-362. doi: 10.34067/KID.0006832022.
IgAN and MCD are the most common glomerular diseases reported after COVID-19 vaccination, particularly after mRNA vaccination. Membranous nephropathy, pauci-immune GN, and collapsing GN have also been attributed to COVID-19 vaccination, some with dual histologies. Recovery of kidney function and proteinuria remission is more likely in IgAN and MCD by 4–6 months compared with the other glomerular diseases.
Patients with glomerular disease (GD) with various renal histologies have been reported after vaccination against SARS-CoV-2. Causality has not been established, and the long-term outcomes are not known. To better characterize the GDs and clinical courses/outcomes, we created the International Registry of COVID-19 vaccination and Glomerulonephritis to study in aggregate patients with GN suspected after COVID-19 vaccine exposure.
A REDCap survey was used for anonymized data collection. Detailed information on vaccination type and timing and GD histology were recorded in the registry. We collected serial information on laboratory values (before and after vaccination and during follow-up), treatments, and kidney-related outcomes.
Ninety-eight patients with GD were entered into the registry over 11 months from 44 centers throughout the world. Median follow-up was 89 days after diagnosis. IgA nephropathy (IgAN) and minimal change disease (MCD) were the most common kidney diseases reported. Recovery of kidney function and remission of proteinuria were more likely in IgAN and MCD at 4–6 months than with pauci-immune GN/vasculitis and membranous nephropathy.
The development of GD after vaccination against SARS-CoV-2 may be a very rare adverse event. Temporal association is present for IgAN and MCD, but causality is not firmly established. Kidney outcomes for IgAN and MCD are favorable. No changes in vaccination risk-benefit assessment are recommended based on these findings.
IgAN 和 MCD 是 COVID-19 疫苗接种后最常见的肾小球疾病,尤其是 mRNA 疫苗接种后。膜性肾病、少免疫性 GN 和塌陷性 GN 也归因于 COVID-19 疫苗接种,其中一些具有双重组织学特征。与其他肾小球疾病相比,IgAN 和 MCD 在 4-6 个月时更有可能恢复肾功能和蛋白尿缓解。
接种 SARS-CoV-2 疫苗后,各种肾脏组织学的肾小球疾病(GD)患者已有报道。因果关系尚未确定,长期结果尚不清楚。为了更好地描述 GD 和临床过程/结果,我们创建了 COVID-19 疫苗接种和肾小球肾炎国际登记处,以汇总研究 COVID-19 疫苗暴露后疑似 GN 的患者。
使用 REDCap 调查进行匿名数据收集。在登记处记录了疫苗类型和时间以及 GD 组织学的详细信息。我们收集了实验室值(接种前后和随访期间)、治疗和肾脏相关结果的系列信息。
在 11 个月的时间里,来自全球 44 个中心的 98 名 GD 患者进入了该登记处。中位随访时间为诊断后 89 天。IgA 肾病(IgAN)和微小病变性肾病(MCD)是报告的最常见肾脏疾病。在 4-6 个月时,IgAN 和 MCD 更有可能恢复肾功能和缓解蛋白尿,而少免疫性 GN/血管炎和膜性肾病则不然。
SARS-CoV-2 疫苗接种后 GD 的发展可能是一种非常罕见的不良事件。IgAN 和 MCD 存在时间关联,但因果关系尚未确定。IgAN 和 MCD 的肾脏结局良好。根据这些发现,不建议改变疫苗的风险效益评估。